Press Release | December 15, 2021
Philip Worboys, Ph.D. Joins Sapient as Head of Translational Science
San Diego, CA—Sapient, a full-service bioanalytical research organization transforming the efficiency of biomarker discovery for pharmaceutical and biotechnology sponsors, announced that Philip Worboys, Ph.D. has joined its leadership team as Head of Translational Science. In this role, Dr. Worboys will work with Sapient’s cross-functional teams to develop and execute scientifically rigorous translational biomarker strategies that inform discovery efforts, streamline validation of findings, and support clinical development.
Dr. Worboys brings with him over 25 years of experience in pharmaceutical research and development across a range of therapeutic areas including CNS, respiratory, inflammation, GI, and cardiovascular indications. Prior to joining Sapient, he was Senior Vice President of Research and Translational Science at Theravance Biopharma, where he led the progression of drug candidates from the discovery stage into clinical studies, overseeing DMPK, clinical pharmacology, and nonclinical safety as well as the medicinal chemistry and biology-pharmacology functions. He previously held roles of increasing seniority at Roche, Pfizer, and Merck. He obtained his B.Sc. in Biochemistry from Imperial College London and his Ph.D. in Drug Metabolism & Pharmacokinetics from the University of Manchester in the UK.
“We are thrilled to have Phil join the Sapient team and to give our customers access to his deep expertise in translating scientific discoveries to clinical impact,” said Mohit Jain, MD, PhD, Founder and CEO of Sapient. “Our mission is not only to profile the unknown factors that contribute to human health and disease, but to make our discoveries actionable in optimizing drug development efforts. Phil will play an invaluable role in this process, supporting rapid translation of our key findings into clinical applications and diagnostic assays.”
“In learning about Sapient, I immediately saw the huge potential the company has to transform the efficiency of drug development today,” said Dr. Worboys. “By accelerating biomarker discovery, we can quickly uncover new pathways associated with disease mechanisms, disease progression, patient response, and more. Linking biomarkers to diseases and treatments has the potential to optimize a drug’s safety and efficacy. I’m excited to help bring sponsors these novel insights, which are critical to prioritize development programs and determine the best routes for clinical advancement.”
Sapient is a full-service bioanalytical research organization that acts as a Discovery Engine for pharmaceutical and biotechnology sponsors. With a mission to solve the inefficiencies of drug development by mapping the thousands of still unknown circulating factors that contribute to human health and disease, Sapient discovers biomarkers with unprecedented speed and at population scale, applying them to optimize drug pipelines and accelerate clinical development.
Its platform combines advanced mass spectrometry-based technologies – able to assay more than 11,000 circulating factors per biosample and handle tens of thousands of samples per day – with computational learning and the world’s largest proprietary human chemical database to deliver actionable insights, based in core biology, to align patients, disease biology, and specific therapies. Biomarkers can be rapidly identified and validated at any phase, enabling understanding of complex disease processes, target elucidation, companion diagnostic development, personalization of therapy, clinical trial enrichment, and pharmacometric modeling. For more information, visit sapient.local.
Head of Marketing, Sapient